Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 7Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms, Castration-Resistant 1Non-metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Bulbo-Spinal Atrophy, X-Linked 1Biochemically Recurrent Prostate Cancer 1Adenocarcinoma 1

Interventions

darolutamide 2Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × darolutamide × 30 days × Clear all
NCT07395804 2026-05-29

23146

Bayer

Recruiting
500 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06661122 2026-05-19

HAYATE

Bayer

Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡